Trippbio, Inc.
🇺🇸United States
Clinical Trials
3
Active:0
Completed:3
Trial Phases
2 Phases
Phase 1:2
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (66.7%)Phase 2
1 (33.3%)An Evaluation of the Effect of Food on the PK of a Novel PanCytoVir™ Suspension (100mg/ml), in Healthy, Adult Volunteers
Phase 1
Completed
- Conditions
- Relative Bioavailability
- Interventions
- Drug: PanCytoVir™
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- TrippBio, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT06025318
- Locations
- 🇮🇳
Vayam Research Solutions Limited, Gujarat, India
A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml)
Phase 1
Completed
- Conditions
- Relative Bioavailability
- Interventions
- Drug: PanCytoVir™ 100 mg/mL oral suspension
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- TrippBio, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT06025344
- Locations
- 🇮🇳
Vayam Research Solutions Limited, Gujrat, India
A Study to Evaluate the Efficacy of PanCytoVir™ for the Treatment of Non-Hospitalized Patients With COVID-19 Infection
Phase 2
Completed
- Conditions
- COVID-19
- Interventions
- Drug: PanCytoVir™ (probenecid)Drug: Placebo
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- TrippBio, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT05442983
- Locations
- 🇮🇳
PCMCs PGI Yashwantrao Chavan Memorial Hospital, Pune, India
News
Probenecid, a Gout Medication, Shows Promise as Broad-Spectrum Antiviral Against COVID-19 and Other Respiratory Viruses
A new study indicates that probenecid, an FDA-approved drug for gout, exhibits broad antiviral properties against SARS-CoV-2, RSV, and influenza viruses.